Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577368 | 1.00 | PDPK1 (0.55) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL1978430 | 1.00 | PDPK1 (0.55) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL9455955 | 0.98 | PDPK1 (0.53) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL10678791 | 0.98 | PDPK1 (0.53) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL7921748 | 0.98 | PDPK1 (0.56) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL4350755 | 0.98 | PDPK1 (0.56) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL10372399 | 0.96 | PDPK1 (0.55) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL4865025 | 0.94 | PDPK1 (0.53) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL9294599 | 0.94 | PDPK1 (0.58) | PDPK1MTORBCHETSHRSLC6A2 | |
| SCHEMBL8194117 | 0.94 | PDPK1 (0.53) | PDPK1MTORBCHETSHRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940373-B1 | 1-FLUORO-1-DEOXY-SCYLLO-INOSITOL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | WARATAH PHARMACEUTICALS INC (CA) | 2015-05-06 | — | — | EP | disclosed |
| EP-1940373-B1 | 1-FLUORO-1-DEOXY-SCYLLO-INOSITOL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | WARATAH PHARMACEUTICALS INC (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| EP-1940373-A4 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DESPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-1940373-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DESPOSITION, ACCUMULATION OR PERSISTENCE | Waratah Pharmaceuticals, Inc. (CA) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007119108-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| WO-2007041855-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERISED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | PDPK1 4204/4885MTOR 780/4885BCHE 1181/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | PDPK1 3301/4885MTOR 1764/4885BCHE 94/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | PDPK1 4242/4885MTOR 1029/4885BCHE 787/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | PDPK1 4274/4885MTOR 1138/4885BCHE 735/4885 |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | SCLY, SMOX, SMS | PDPK1 4204/4885MTOR 780/4885BCHE 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.